Local view for "http://purl.org/linkedpolitics/eu/plenary/2009-11-24-Speech-2-386"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20091124.35.2-386"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:translated text |
"Mr Mölzer, this question simply does not arise, as it was comprehensively examined and decided upon in connection with the pharmaceuticals package that the Commission proposed last year. We have clear and unambiguous case-law on this matter from the European Court of Justice, which includes parallel trade in medicines in the freedom of the internal market, and there is therefore no legal scope to counter this.
The pharmaceuticals package proposed by the Commission over the last year does not set out any specific rules that negatively affect parallel trade in any way. In the very important and far-reaching proposals that relate to protection against counterfeit medicines in the legal supply chain, exactly the same rules apply to the manufacturers of medicines as to those carrying out parallel trading. There is no discrimination at all. I am not aware of there being anyone in the Commission with the intention of dealing with this subject."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples